Bioinorganic Medicinal Chemistry (eBook, ePUB)
Redaktion: Alessio, Enzo
165,99 €
165,99 €
inkl. MwSt.
Sofort per Download lieferbar
0 °P sammeln
165,99 €
Als Download kaufen
165,99 €
inkl. MwSt.
Sofort per Download lieferbar
0 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
165,99 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
0 °P sammeln
Bioinorganic Medicinal Chemistry (eBook, ePUB)
Redaktion: Alessio, Enzo
- Format: ePub
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Edited by a renowned and experienced lecturer, this handbook and reference provides an in-depth overview of this key area in medicine and bioinorganic chemistry, detailing such topics as targeting strategies, mechanism of action, Pt-based antitumor drugs and radiopharmaceuticals.
- Geräte: eReader
- mit Kopierschutz
- eBook Hilfe
- Größe: 10.15MB
Andere Kunden interessierten sich auch für
- Bioinorganic Medicinal Chemistry (eBook, PDF)165,99 €
- Florencio Zaragoza DörwaldLead Optimization for Medicinal Chemists (eBook, ePUB)156,99 €
- Paul M. DewickMedicinal Natural Products (eBook, ePUB)45,99 €
- ADMET for Medicinal Chemists (eBook, ePUB)134,99 €
- Rosaleen AndersonAntibacterial Agents (eBook, ePUB)44,99 €
- Denise BohrerSources of Contamination in Medicinal Products and Medical Devices (eBook, ePUB)144,99 €
- John J. TobinMedical Product Regulatory Affairs (eBook, ePUB)88,99 €
-
-
-
Edited by a renowned and experienced lecturer, this handbook and reference provides an in-depth overview of this key area in medicine and bioinorganic chemistry, detailing such topics as targeting strategies, mechanism of action, Pt-based antitumor drugs and radiopharmaceuticals.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Wiley-VCH
- Seitenzahl: 422
- Erscheinungstermin: 28. Februar 2011
- Englisch
- ISBN-13: 9783527633128
- Artikelnr.: 37354681
- Verlag: Wiley-VCH
- Seitenzahl: 422
- Erscheinungstermin: 28. Februar 2011
- Englisch
- ISBN-13: 9783527633128
- Artikelnr.: 37354681
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Enzo Alessio was born in 1958, studied chemistry at the University of Trieste (Italy) and received his Ph D from the University of Ferrara (Italy) in 1989. After a NATO-CNR postdoctoral fellowship with Luigi G. Marzilli at Emory University (Atlanta), he became first Research Associate and then Associate Professor of Inorganic Chemistry at the University of Trieste, where he is now director of the Ph D School in Chemistry. He is co-author of more than 150 publications and 10 patents in the fields of coordination chemistry, metal-based anticancer drugs, and metal-driven construction of supramolecular architectures, in particular multi-chromophore assemblies for photophysical applications.
MEDICINAL INORGANIC CHEMISTRY: STATE OF THE ART, NEW TRENDS, AND A VISION OF THE FUTURE
Introduction
Antimicrobial Agents
Antiviral Agents
Systemic and Metabolic Diseases Including Inflammation
Metal Chelating Agents
Antiarthritic Drugs and Inflammation
Bipolar Disorder
Anticancer Agents
Small Molecule Delivery and Control
Diagnostic Agents
Veterinary Medicinal Inorganic Chemistry
Conclusions and Vision
TARGETING STRATEGIES FOR METAL-BASED THERAPEUTICS
Introduction
Physiological Targeting
Molecular Targeting
Immunological Targeting
Concluding Remarks
CURRENT STATUS AND MECHANISM OF ACTION OF PLATINUM-BASED ANTICANCER DRUGS
Introduction
Mechanism of Action of Cisplatin
Limitations of Current Platinum-Based Compounds: New Strategies
Novel Concepts in the Development of Platinum Antitumor Drugs
Concluding Remarks
NEW TRENDS AND FUTURE DEVELOPMENTS OF PLATINUM-BASED ANTITUMOR DRUGS
Introduction
Mechanisms of Action and Resistance
Monofunctional Platinum(II) Complexes
Trans-Platinum(II) Complexes
Multinuclear Platinum(II) C omplexes
Platinum(IV) Complexes
Delivery of Platinum Drugs
Concluding Remarks and Future Perspectives
RUTHENIUM AND OTHER NON-PLATINUM ANTICANCER COMPOUNDS
Introduction
Ruthenium Anticancer Compounds
From Gallium Nitrate to Oral Gallium Complexes
Titanium Anticancer Compounds
Ferrocene-Derived Anticancer Agents
The Main Group Organometallics Spirogermanium and Germanium-132
Arsenic in Cancer Chemotherapy
Overcoming the Resistance of Tumors to Anticancer Agents by Rare Earth Element Compounds
Conclusions
THE CHALLENGE OF ESTABLISHING RELIABLE SCREENING TESTS FOR SELECTING ANTICANCER METAL COMPOUNDS
Introduction
Tumor Cell Growth Inhibition and Cell Death Screening Assays
Metal-Based Anticancer Compounds and Gene Expression Microarray Technologies
Metal-Based Anticancer Compounds and the Proteomic Approach
Concluding Remarks
GOLD-BASED THERAPEUTIC AGENTS: A NEW PERSPECTIVE
Introduction
Biological Chemistry of Gold
Gold Antiarthritic Drugs
Gold Complexes as Anticancer Agents
Gold Complexes as Antiparasitic Agents
Concluding Remarks
MRI CONTRAST AGENTS: STATE OF THE ART AND NEW TRENDS
Introduction
T1 Agents
T2-Susceptibility Agents
CEST Agents
Concluding Remarks
METAL-BASED RADIOPHARMACEUTICALS
Introduction
Selected Examples: Therapeutic Radiopharmaceuticals
Diagnostic Metal-Based Radiopharmaceuticals
Perspectives and Conclusion
BORON AND GADOLINIUM IN THE NEUTRON CAPTURE THERAPY OF CANCER
Introduction
Boron Neutron Capture Therapy
Role of Medicinal Inorganic Chemistry in BNCT
Gadolinium Neutron Capture Therapy
Conclusions and Future Outlook
ESSENTIAL METAL RELATED METABOLIC DISORDERS
Introduction: What is Essentiality?
Iron Metabolic Diseases: Acquired and Genetic
Copper Metabolic Diseases
Zinc Metabolic Diseases
Diseases Related to Imbalances in Electrolytic Metabolism: P, the Alkali Metals, and the Alkaline Earths
Metabolism of Other Trace Elements
Conclusions
METAL COMPOUNDS AS ENZYME INHIBITORS
Introduction
Kinase Inhibitors
Proteasome Inhibitors
Carbonic Anhydrase Inhibitors (CAIs)
Cyclooxygenase Inhibitors
Acetylcholinesterase Inhibitors
Protein Phosphatase Inhibitors
Trypsin and Thrombin Inhibitors
Cysteine Protease Inhibitors and Glutathione Transferase Inhibitors
HIV-1 Reverse Transcriptase and Protease Inhibitors
Telomerase Inhibitors
Zinc Finger Protein Inhibitors
CXCR4 Inhibitors
Xanthine Oxidase Inhibitors
Miscellaneous Protein Inhibitors and Conclusions
BIOMEDICAL APPLICATIONS OF METAL-CONTAINING LUMINOPHORES
Introduction: Luminescence in Diagnostics and Imaging
Transition-Metal Containing Luminescent Agents
Lanthanide-Based Luminophores
Nanoparticle-Based Luninophores
Conclusions and Perspectives
Introduction
Antimicrobial Agents
Antiviral Agents
Systemic and Metabolic Diseases Including Inflammation
Metal Chelating Agents
Antiarthritic Drugs and Inflammation
Bipolar Disorder
Anticancer Agents
Small Molecule Delivery and Control
Diagnostic Agents
Veterinary Medicinal Inorganic Chemistry
Conclusions and Vision
TARGETING STRATEGIES FOR METAL-BASED THERAPEUTICS
Introduction
Physiological Targeting
Molecular Targeting
Immunological Targeting
Concluding Remarks
CURRENT STATUS AND MECHANISM OF ACTION OF PLATINUM-BASED ANTICANCER DRUGS
Introduction
Mechanism of Action of Cisplatin
Limitations of Current Platinum-Based Compounds: New Strategies
Novel Concepts in the Development of Platinum Antitumor Drugs
Concluding Remarks
NEW TRENDS AND FUTURE DEVELOPMENTS OF PLATINUM-BASED ANTITUMOR DRUGS
Introduction
Mechanisms of Action and Resistance
Monofunctional Platinum(II) Complexes
Trans-Platinum(II) Complexes
Multinuclear Platinum(II) C omplexes
Platinum(IV) Complexes
Delivery of Platinum Drugs
Concluding Remarks and Future Perspectives
RUTHENIUM AND OTHER NON-PLATINUM ANTICANCER COMPOUNDS
Introduction
Ruthenium Anticancer Compounds
From Gallium Nitrate to Oral Gallium Complexes
Titanium Anticancer Compounds
Ferrocene-Derived Anticancer Agents
The Main Group Organometallics Spirogermanium and Germanium-132
Arsenic in Cancer Chemotherapy
Overcoming the Resistance of Tumors to Anticancer Agents by Rare Earth Element Compounds
Conclusions
THE CHALLENGE OF ESTABLISHING RELIABLE SCREENING TESTS FOR SELECTING ANTICANCER METAL COMPOUNDS
Introduction
Tumor Cell Growth Inhibition and Cell Death Screening Assays
Metal-Based Anticancer Compounds and Gene Expression Microarray Technologies
Metal-Based Anticancer Compounds and the Proteomic Approach
Concluding Remarks
GOLD-BASED THERAPEUTIC AGENTS: A NEW PERSPECTIVE
Introduction
Biological Chemistry of Gold
Gold Antiarthritic Drugs
Gold Complexes as Anticancer Agents
Gold Complexes as Antiparasitic Agents
Concluding Remarks
MRI CONTRAST AGENTS: STATE OF THE ART AND NEW TRENDS
Introduction
T1 Agents
T2-Susceptibility Agents
CEST Agents
Concluding Remarks
METAL-BASED RADIOPHARMACEUTICALS
Introduction
Selected Examples: Therapeutic Radiopharmaceuticals
Diagnostic Metal-Based Radiopharmaceuticals
Perspectives and Conclusion
BORON AND GADOLINIUM IN THE NEUTRON CAPTURE THERAPY OF CANCER
Introduction
Boron Neutron Capture Therapy
Role of Medicinal Inorganic Chemistry in BNCT
Gadolinium Neutron Capture Therapy
Conclusions and Future Outlook
ESSENTIAL METAL RELATED METABOLIC DISORDERS
Introduction: What is Essentiality?
Iron Metabolic Diseases: Acquired and Genetic
Copper Metabolic Diseases
Zinc Metabolic Diseases
Diseases Related to Imbalances in Electrolytic Metabolism: P, the Alkali Metals, and the Alkaline Earths
Metabolism of Other Trace Elements
Conclusions
METAL COMPOUNDS AS ENZYME INHIBITORS
Introduction
Kinase Inhibitors
Proteasome Inhibitors
Carbonic Anhydrase Inhibitors (CAIs)
Cyclooxygenase Inhibitors
Acetylcholinesterase Inhibitors
Protein Phosphatase Inhibitors
Trypsin and Thrombin Inhibitors
Cysteine Protease Inhibitors and Glutathione Transferase Inhibitors
HIV-1 Reverse Transcriptase and Protease Inhibitors
Telomerase Inhibitors
Zinc Finger Protein Inhibitors
CXCR4 Inhibitors
Xanthine Oxidase Inhibitors
Miscellaneous Protein Inhibitors and Conclusions
BIOMEDICAL APPLICATIONS OF METAL-CONTAINING LUMINOPHORES
Introduction: Luminescence in Diagnostics and Imaging
Transition-Metal Containing Luminescent Agents
Lanthanide-Based Luminophores
Nanoparticle-Based Luninophores
Conclusions and Perspectives
MEDICINAL INORGANIC CHEMISTRY: STATE OF THE ART, NEW TRENDS, AND A VISION OF THE FUTURE
Introduction
Antimicrobial Agents
Antiviral Agents
Systemic and Metabolic Diseases Including Inflammation
Metal Chelating Agents
Antiarthritic Drugs and Inflammation
Bipolar Disorder
Anticancer Agents
Small Molecule Delivery and Control
Diagnostic Agents
Veterinary Medicinal Inorganic Chemistry
Conclusions and Vision
TARGETING STRATEGIES FOR METAL-BASED THERAPEUTICS
Introduction
Physiological Targeting
Molecular Targeting
Immunological Targeting
Concluding Remarks
CURRENT STATUS AND MECHANISM OF ACTION OF PLATINUM-BASED ANTICANCER DRUGS
Introduction
Mechanism of Action of Cisplatin
Limitations of Current Platinum-Based Compounds: New Strategies
Novel Concepts in the Development of Platinum Antitumor Drugs
Concluding Remarks
NEW TRENDS AND FUTURE DEVELOPMENTS OF PLATINUM-BASED ANTITUMOR DRUGS
Introduction
Mechanisms of Action and Resistance
Monofunctional Platinum(II) Complexes
Trans-Platinum(II) Complexes
Multinuclear Platinum(II) C omplexes
Platinum(IV) Complexes
Delivery of Platinum Drugs
Concluding Remarks and Future Perspectives
RUTHENIUM AND OTHER NON-PLATINUM ANTICANCER COMPOUNDS
Introduction
Ruthenium Anticancer Compounds
From Gallium Nitrate to Oral Gallium Complexes
Titanium Anticancer Compounds
Ferrocene-Derived Anticancer Agents
The Main Group Organometallics Spirogermanium and Germanium-132
Arsenic in Cancer Chemotherapy
Overcoming the Resistance of Tumors to Anticancer Agents by Rare Earth Element Compounds
Conclusions
THE CHALLENGE OF ESTABLISHING RELIABLE SCREENING TESTS FOR SELECTING ANTICANCER METAL COMPOUNDS
Introduction
Tumor Cell Growth Inhibition and Cell Death Screening Assays
Metal-Based Anticancer Compounds and Gene Expression Microarray Technologies
Metal-Based Anticancer Compounds and the Proteomic Approach
Concluding Remarks
GOLD-BASED THERAPEUTIC AGENTS: A NEW PERSPECTIVE
Introduction
Biological Chemistry of Gold
Gold Antiarthritic Drugs
Gold Complexes as Anticancer Agents
Gold Complexes as Antiparasitic Agents
Concluding Remarks
MRI CONTRAST AGENTS: STATE OF THE ART AND NEW TRENDS
Introduction
T1 Agents
T2-Susceptibility Agents
CEST Agents
Concluding Remarks
METAL-BASED RADIOPHARMACEUTICALS
Introduction
Selected Examples: Therapeutic Radiopharmaceuticals
Diagnostic Metal-Based Radiopharmaceuticals
Perspectives and Conclusion
BORON AND GADOLINIUM IN THE NEUTRON CAPTURE THERAPY OF CANCER
Introduction
Boron Neutron Capture Therapy
Role of Medicinal Inorganic Chemistry in BNCT
Gadolinium Neutron Capture Therapy
Conclusions and Future Outlook
ESSENTIAL METAL RELATED METABOLIC DISORDERS
Introduction: What is Essentiality?
Iron Metabolic Diseases: Acquired and Genetic
Copper Metabolic Diseases
Zinc Metabolic Diseases
Diseases Related to Imbalances in Electrolytic Metabolism: P, the Alkali Metals, and the Alkaline Earths
Metabolism of Other Trace Elements
Conclusions
METAL COMPOUNDS AS ENZYME INHIBITORS
Introduction
Kinase Inhibitors
Proteasome Inhibitors
Carbonic Anhydrase Inhibitors (CAIs)
Cyclooxygenase Inhibitors
Acetylcholinesterase Inhibitors
Protein Phosphatase Inhibitors
Trypsin and Thrombin Inhibitors
Cysteine Protease Inhibitors and Glutathione Transferase Inhibitors
HIV-1 Reverse Transcriptase and Protease Inhibitors
Telomerase Inhibitors
Zinc Finger Protein Inhibitors
CXCR4 Inhibitors
Xanthine Oxidase Inhibitors
Miscellaneous Protein Inhibitors and Conclusions
BIOMEDICAL APPLICATIONS OF METAL-CONTAINING LUMINOPHORES
Introduction: Luminescence in Diagnostics and Imaging
Transition-Metal Containing Luminescent Agents
Lanthanide-Based Luminophores
Nanoparticle-Based Luninophores
Conclusions and Perspectives
Introduction
Antimicrobial Agents
Antiviral Agents
Systemic and Metabolic Diseases Including Inflammation
Metal Chelating Agents
Antiarthritic Drugs and Inflammation
Bipolar Disorder
Anticancer Agents
Small Molecule Delivery and Control
Diagnostic Agents
Veterinary Medicinal Inorganic Chemistry
Conclusions and Vision
TARGETING STRATEGIES FOR METAL-BASED THERAPEUTICS
Introduction
Physiological Targeting
Molecular Targeting
Immunological Targeting
Concluding Remarks
CURRENT STATUS AND MECHANISM OF ACTION OF PLATINUM-BASED ANTICANCER DRUGS
Introduction
Mechanism of Action of Cisplatin
Limitations of Current Platinum-Based Compounds: New Strategies
Novel Concepts in the Development of Platinum Antitumor Drugs
Concluding Remarks
NEW TRENDS AND FUTURE DEVELOPMENTS OF PLATINUM-BASED ANTITUMOR DRUGS
Introduction
Mechanisms of Action and Resistance
Monofunctional Platinum(II) Complexes
Trans-Platinum(II) Complexes
Multinuclear Platinum(II) C omplexes
Platinum(IV) Complexes
Delivery of Platinum Drugs
Concluding Remarks and Future Perspectives
RUTHENIUM AND OTHER NON-PLATINUM ANTICANCER COMPOUNDS
Introduction
Ruthenium Anticancer Compounds
From Gallium Nitrate to Oral Gallium Complexes
Titanium Anticancer Compounds
Ferrocene-Derived Anticancer Agents
The Main Group Organometallics Spirogermanium and Germanium-132
Arsenic in Cancer Chemotherapy
Overcoming the Resistance of Tumors to Anticancer Agents by Rare Earth Element Compounds
Conclusions
THE CHALLENGE OF ESTABLISHING RELIABLE SCREENING TESTS FOR SELECTING ANTICANCER METAL COMPOUNDS
Introduction
Tumor Cell Growth Inhibition and Cell Death Screening Assays
Metal-Based Anticancer Compounds and Gene Expression Microarray Technologies
Metal-Based Anticancer Compounds and the Proteomic Approach
Concluding Remarks
GOLD-BASED THERAPEUTIC AGENTS: A NEW PERSPECTIVE
Introduction
Biological Chemistry of Gold
Gold Antiarthritic Drugs
Gold Complexes as Anticancer Agents
Gold Complexes as Antiparasitic Agents
Concluding Remarks
MRI CONTRAST AGENTS: STATE OF THE ART AND NEW TRENDS
Introduction
T1 Agents
T2-Susceptibility Agents
CEST Agents
Concluding Remarks
METAL-BASED RADIOPHARMACEUTICALS
Introduction
Selected Examples: Therapeutic Radiopharmaceuticals
Diagnostic Metal-Based Radiopharmaceuticals
Perspectives and Conclusion
BORON AND GADOLINIUM IN THE NEUTRON CAPTURE THERAPY OF CANCER
Introduction
Boron Neutron Capture Therapy
Role of Medicinal Inorganic Chemistry in BNCT
Gadolinium Neutron Capture Therapy
Conclusions and Future Outlook
ESSENTIAL METAL RELATED METABOLIC DISORDERS
Introduction: What is Essentiality?
Iron Metabolic Diseases: Acquired and Genetic
Copper Metabolic Diseases
Zinc Metabolic Diseases
Diseases Related to Imbalances in Electrolytic Metabolism: P, the Alkali Metals, and the Alkaline Earths
Metabolism of Other Trace Elements
Conclusions
METAL COMPOUNDS AS ENZYME INHIBITORS
Introduction
Kinase Inhibitors
Proteasome Inhibitors
Carbonic Anhydrase Inhibitors (CAIs)
Cyclooxygenase Inhibitors
Acetylcholinesterase Inhibitors
Protein Phosphatase Inhibitors
Trypsin and Thrombin Inhibitors
Cysteine Protease Inhibitors and Glutathione Transferase Inhibitors
HIV-1 Reverse Transcriptase and Protease Inhibitors
Telomerase Inhibitors
Zinc Finger Protein Inhibitors
CXCR4 Inhibitors
Xanthine Oxidase Inhibitors
Miscellaneous Protein Inhibitors and Conclusions
BIOMEDICAL APPLICATIONS OF METAL-CONTAINING LUMINOPHORES
Introduction: Luminescence in Diagnostics and Imaging
Transition-Metal Containing Luminescent Agents
Lanthanide-Based Luminophores
Nanoparticle-Based Luninophores
Conclusions and Perspectives